# ACP-104 in Acutely Psychotic Subjects With Schizophrenia

> **NCT00490516** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 247 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ACP-104
- **DRUG:** ACP-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00490516
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490516, "ACP-104 in Acutely Psychotic Subjects With Schizophrenia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00490516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*